Clinical trial · Interventional
Strive Cardio for Endometrial Cancer Survivors
The Effect of Combined Aerobic and Muscle Strengthening Exercises on Structural and Functional Cardiovascular Adaptations in Endometrial Cancer Survivors
NCT06534008CI-TRIAL-00097615completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
STRIVE Cardio is a 12-week exercise intervention study with the goal to improve functional fitness and cardiovascular health for women who have completed treatment for non-metastatic endometrial cancer within the last five years and are currently in remission. Measures will include a functional fitness test, carotid-femoral pulse wave velocity, brachial artery flow mediated dilation, and a blood draw. Participants will be provided resistance bands, a dumbbell, and a Fitbit to keep. Participants will be compensated $50 for each of their two in-person visits.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 12-week home-based exercise intervention | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 12-week Exercise Intervention
- description
- In this single-arm study, every participant will be enrolled in the 12-week distance-based exercise intervention. All participants will receive an exercise regimen and the necessary materials to complete and measure their exercise. All participants will receive weekly online heath coaching.
- interventionNames
- Behavioral: 12-week home-based exercise intervention
Primary outcomes (1)
- measure
- Changes in Vascular Stiffness Following Distance-Based Exercise Program
- timeFrame
- 14 weeks
- description
- Within participant change from pre- to post-intervention as measured by carotid-femoral pulse wave velocity, which is a measure of speed that is directly related to the stiffness of the arteries/vessels of the body.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Willing and able to provide written informed consent * Willing to comply with study procedures and available for the duration of the study * Fluent in spoken and written English * Women 18 years of age or older * Documented diagnosis of Type I, stage I-IIIc endometrial cancer within the past 5 years * Completion of current cytotoxic treatment for endometrial cancer * Technology access (phone call access, broadband internet, Wi-Fi) for tele coaching * Comfort and willingness to use technology (videoconferencing) throughout the study for coaching * Pass the Physical Activity Readiness Questionnaire (PAR-Q) * Medical clearances given by their primary provider / oncologist (if indicated by the PAR-Q) Exclusion Criteria * Absolute contraindications to exercise (i.e., acute myocardial infarction, severe orthopedic or musculoskeletal limitations) * History of previous myocardial infarction, ischemia, or hemorrhagic stroke * Medically documented history of heart disease including heart valve disease, coronary artery disease, heart failure, peripheral artery disease, aortic disease, pericardial disease, cerebrovascular disease, or deep vein thrombosis * Medical documentation of treatment-resistant hypertension OR taking ≥2 medications to treat hypertension * Medically documented history of cardiovascular disease including (but not limited to): bypass surgery, stent procedures, bypass grafts, or coronary angioplasty * Medically documented or self-reported type 1 diabetes (insulin-dependents) * Prescriptions for or use of semaglutide (GLP-1 agonists) including name brands: Ozempic, Wegovy or Mounjaro * Current or recent (within last 3 months) use of hormone replacement therapy (HRT) * Evidence of recurrent or metastatic disease * Currently performing resistance training ≥2 days per week * Currently exceeding 150 minutes of at least moderate intensity exercise per week * Report of chest pain, shortness of breath, fainting, or angina pectoris * Self-reported history of falling, fall risk * Have physical disability that would limit range of motion through exercises such as sitting, standing and inability to walk one block * Plans to move from the area * Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to study enrollment * Self-reported tobacco use in last 7 days, current smoking, current tobacco use including e-cigarettes and vaping devices * Not suitable for study participation due to other reasons at the discretion of the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.